CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Area of Science:

• Oncology
• Immunotherapy
• Nuclear Medicine

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has transformed hematologic malignancy treatment.
• Several CAR T-cell products are FDA-approved, with ongoing research to improve efficacy and safety.
• Nuclear medicine is integral to staging, response assessment, and monitoring adverse effects.

Purpose of the Study:

• To introduce CAR T-cell therapy.
• To highlight nuclear medicine practices and innovations in CAR T-cell therapy care.
• To emphasize the need for continued advancements in medical imaging for this field.

Main Methods:

• Review of current literature on CAR T-cell therapy.
• Discussion of established nuclear medicine techniques.
• Exploration of novel imaging innovations.

Main Results:

• CAR T-cell therapy shows significant promise in treating blood cancers.
• Nuclear medicine plays a key role in optimizing CAR T-cell therapy.
• Imaging aids in staging, assessing treatment response, and monitoring side effects.

Conclusions:

• CAR T-cell therapy is a revolutionary treatment for hematologic malignancies.
• Nuclear medicine imaging is essential for the successful application and advancement of CAR T-cell therapy.
• Continued innovation in medical imaging is crucial as CAR T-cell therapy evolves.